Abbisko Therapeutics Co, Ltd

This early-stage study tests a new drug called ABSK-011 in people with advanced solid tumors, especially liver cancer. The main goal is to check the drug's safety and how the body processes it. About 200 participants will take the drug by mouth, and researchers will monitor side …

This early-stage study tests an experimental pill called ABSK021 in people with advanced solid tumors (including a rare joint tumor called TGCT) who have run out of standard options. The main goal is to check safety and find the right dose, while also seeing if the drug can shrin…

This study tests a new drug called ABSK-011 for people with advanced liver cancer that has not responded to previous treatments. The drug targets a specific protein (FGF19) found in some tumors. About 141 participants will receive either ABSK-011 or a placebo, both with standard …

This study tests a new drug called ABSK141 in 401 adults with advanced solid tumors that have a specific gene change called KRAS G12D. The goal is to see if the drug is safe, tolerable, and how well it works. The study is open-label, meaning everyone knows they are getting the dr…

This early-phase study tests a new oral drug, ABSK131, in adults with advanced solid tumors that have lost the MTAP gene. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors or slow their growth. About 266 participants will take the drug…

This study follows 260 children with achondroplasia (a type of dwarfism) for up to 2 years to collect information on their growth, medical issues, and quality of life. No treatments or drugs are given—it is purely observational. The goal is to better understand the natural course…